Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study on QTc prolongation after parenteral haloperidol for acute agitation in hospitalized psychiatric patients
TCTR20240417001Completed
- Sponsor
- Buddhachinaraj Phitsanulok Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of haloperidol in agitation (acute) and mental disorder, sponsored by Buddhachinaraj Phitsanulok Hospital. Primary endpoint: QTc prolongation after haloperidol administration. Started Aug 2024; status: completed.
02
Drugs
haloperidol
03
Conditions
agitation (acute)mental disorder
Beyond the preview
Go deeper on TCTR20240417001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240417001.